The chief scientific officer at 23andMe is leaving his role at the consumer genetics company, four years after his arrival helped energize its move toward drug discovery.
Richard Scheller, a Genentech veteran, has joined the Palo Alto, Calif.-based BridgeBio (BBIO) as chairman of research and development, according to Securities and Exchange Commission filings. Scheller remains on 23andMe’s board of directors.
On Tuesday, Scheller also joined the board of San Francisco-based, venture-backed Maze Therapeutics, which is working on drugs that target “genetic modifiers” that can modulate how much a genetic condition actually affects a given person.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect